Key Takeaways The S&P 500 slipped less than 0.1% on Friday, May 30, 2025, as President Trump rekindled his tough rhetoric on ...

Kymera Therapeutics (NASDAQ:KYMR) rose ~16% in after-hours trading Friday after the company announced it would release phase 1 data of its inflammatory diseases oral candidate KT-621 in healthy ...

US stocks end little changed after Trump says China violated tariff terms. Administration maps new curbs. Investors shrug off ...

Live Updates Live Coverage Updates appear automatically as they are published. Positive Economic Signs 11:10 am by Gerelyn ...

Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $808.67, a high ...

Wall Street absorbed a fresh wave of tariff uncertainty after a federal appeals court reinstated President Trump's global ...

Regeneron’s stock is having its worst day in 14 years after the failure of late-stage trial of its COPD treatment, after ...

NASDAQ has also managed to rebound from session lows, supported by Trump’s comments on potential negotiations with Xi.

Intellia’s stock fell 23% after one patient in its Phase III MAGNITUDE trial developed severe liver toxicity that later ...

Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...

What Happened? Shares of biotech company Regeneron (NASDAQ:REGN) fell 19% in the afternoon session after the company ...

Live Updates Live Coverage Updates appear automatically as they are published. Jamie Dimon Weighs in on Rates 12:46 pm by ...